Trial Profile
Phase II Study of Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Dec 2021 Status changed from active, no longer recruiting to completed.
- 28 Oct 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 28 Oct 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.